BeyondSpring Inc (BYSI)

  • Get an in-depth profile of BeyondSpring Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
1.12 -0.05 (-4.27%)
Closed USD Disclaimer
1.12 0.00 (0.00%)

BeyondSpring Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
103
Equity Type
ORD
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. Its Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin activates immune defense protein GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
Contact Information
Address
New York,10005 United States
Phone
646 305 6387
Fax
-
Web
https://www.beyondspringpharma.com
Top Executives
Name
Age
Since
Title
Lan Huang 50 2014 Co-Founder, Chairman & CEO
Quanqi Song 56 2016 Independent Director
Yan Sun 0 0000 Member of Scientific Advisors & Principal Investigators Board
David S. Ettinger 0 0000 Member of Scientific Advisors & Principal Investigators Board
Jiangwen Majeti 0 2022 Director
Jeffrey Crawford 0 0000 Member of Scientific Advisors & Principal Investigators Board
Douglas W. Blayney 73 0000 Member of Scientific Advisors & Principal Investigators Board
Patrick Fabbio 55 2018 Independent Director
Yuankai Shi 0 0000 Member of Scientific Advisors & Principal Investigators Board
Yanbin Xie 65 2016 Independent Director
Matthew Kirkby 54 2016 Independent Director
Brendan P. Delaney 47 2021 Independent Director
Sihai Xu 0 2022 Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.